AXSM — Axsome Therapeutics, Inc. catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

3 verified catalyst event(s) for Axsome Therapeutics, Inc. (ticker AXSM). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-12-01 — Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfet · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-12 (month) in 4mo ESTIMATED	READOUT Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Phase 3 · Binge-Eating Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 150 mg, Solriamfetol 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shif Phase 3 · Excessive Sleepiness, Shift-work Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 150 mg, Solriamfetol 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder Phase 3 · Binge-Eating Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 75mg, 150 mg, or 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change